How HSCC Is Redefining AI Vendor Transparency for Healthcare

Q: What is an AI-BOM?

An AI Bill of Materials (AIBOM) is a transparency tool that documents the parts and supply chain dependencies inside an AI product. For healthcare organizations, it sheds light on AI components, training data sources, model lineage, APIs, data flows, use cases, and third- and fourth-party subcontractors. That makes it easier to spot hidden risks, surface shadow AI, and map the AI supply chain.

Healthcare teams should stop taking AI vendor claims at face value. In April 2026, HSCC published a guide that tells buyers to ask for proof on model use, training data, supply chain links, security controls, named owners, and post-launch review.

Here’s the short version:

HSCC wants proof, not vendor promises
AI risk in healthcare can affect patient care, privacy, and contract review
The guide points buyers to a standard disclosure package
It also ties those disclosures to risk tiers, contract terms, and review teams
HSCC represents more than 480 healthcare organizations, which gives this guide weight across providers, payers, life sciences, and health IT

What stood out to me is that HSCC treats AI transparency as a buying issue and a patient-safety issue. If a vendor cannot show where training data came from, which third parties are involved, or how model changes are tracked after launch, I’d treat that as a direct review flag.

I’d boil the article down to this: ask for evidence, send each piece to the right internal team, tier the tool by risk, and make the vendor’s promises part of the contract. That is the core shift HSCC is pushing.

AI Vendor Contracting in Health Care: Practical Realities for Legal and Compliance Teams

What HSCC Means by AI Vendor Transparency

HSCC

HSCC treats AI vendor transparency as proof, not survey responses. Vendors need to show how the system was built, what data trained it, who owns it, and how it is watched after deployment. HSCC’s April 2026 Health Industry Third Party AI Risk and Supply Chain Transparency Guide sets that bar for healthcare groups buying AI tools for clinical, operational, and administrative use cases ^[1]^[2].

Put simply, this is the disclosure package HSCC expects healthcare buyers to ask for and check.

Key Disclosure Elements HSCC Expects Vendors to Provide

HSCC puts the focus on the AI Bill of Materials (AI-BOM), data lineage, model auditability, governance, and monitoring ^[1]^[2]. These disclosures give teams what they need for risk tiering and review.

Disclosure Category	What Vendors Must Provide
Model Purpose	Clinical, operational, or administrative use
Supply Chain	AI-BOM: subcontractors, open-source assets, offshore dependencies
Data Integrity	Training data lineage, validation, synthetic data use
Risk Profile	Known vulnerabilities and abuse cases
Governance	Named owners, decision roles, and audit-ready documentation
Monitoring	Post-deployment monitoring and incident response

HSCC also expects contract-level transparency. That means these disclosures shouldn’t sit in a slide deck or sales packet. They should be tied to enforceable contract language and governance-ready definitions from the HSCC AI Cyber Glossary, so clinical, legal, and IT teams are working from the same terms ^[1]^[2].

How Clearer Disclosures Change Risk Decisions

When vendors give structured disclosures, procurement and compliance teams can act on evidence instead of promises.

For example, an AI-BOM can show right away whether a tool relies on open-source assets or subcontractors that add hidden dependencies. That changes the review in a big way. Instead of asking, “Do we trust this vendor?” teams can ask, “What exactly is in this stack, and where are the weak spots?”

Data lineage disclosures matter just as much. If a vendor can’t document where its training data came from or how it was validated, that’s a direct risk flag. In healthcare, that gap can affect privacy review, compliance review, and internal sign-off.

Post-deployment monitoring plans answer another plain but important question: what happens after go-live? A vendor that can track performance, spot issues, and respond to incidents is in a very different position from one that goes quiet once the contract is signed.

With clear disclosures in hand, provider, payer, and health IT teams can decide whether to approve, conditionally approve, remediate, or reject a vendor. The next section turns those disclosures into a practical vendor-request checklist.

What to Request From AI Vendors: A Practical Disclosure Checklist

The hard part is turning HSCC's disclosure categories into something your team can actually request from vendors. This list helps you turn those disclosures into a procurement request instead of drifting into a sales call.

The Minimum Disclosure Package

Before your organization moves past intake, every AI vendor should provide documents across these core areas, no matter their size or use case:

Model purpose, limits, and prohibited uses - What the AI does, what it was built to do, where it should not be used, and any known edge cases.
Training data source, synthetic-data use, and validation method - Where the training data came from, whether synthetic data was used, and how the source was checked. If provenance is missing, treat that as a risk flag.
Performance and bias results - Validation results that show how the model performs in clinical or operational settings, including any known bias findings.
Named subcontractors, open-source components, and offshore contributors - A full inventory of every third party involved in building or maintaining the model.
Security architecture - Controls against adversarial inference, training data leakage, and infrastructure vulnerabilities.
Human oversight requirements - The level of clinician or staff review the system needs, and when the AI should not be used without human confirmation.
Incident handling and change notification - How the vendor handles failures, drift, incidents, and material changes.

HSCC's appendices include questionnaires mapped to these categories.

Which Internal Teams Should Review Each Disclosure Category

Each disclosure should go to the team that owns the decision tied to it. Put simply: the people who live with the risk should review the evidence.

Disclosure Category	What It Tells the Organization	Primary Internal Reviewer
Model Purpose, Limits & Prohibited Uses	Defines the AI's purpose, limitations, and clinical boundaries	Clinical Leadership / AI Governance
Training Data Source, Synthetic-Data Use & Validation	Identifies risks of bias, data leakage, or synthetic data misuse	Privacy / Compliance / Clinical
Security Architecture & Adversarial Risk	Details controls against adversarial inference and infrastructure vulnerabilities	Security (CISO) / IT
Named Subcontractors, Open-Source Components & Offshore Contributors	Reveals risks in the sub-supply chain	Procurement / Enterprise Risk
Validation & Performance Results	Provides evidence of accuracy and reliability in real-world settings	Clinical Leadership / Quality Assurance
Governance & RACI Records	Establishes accountability and oversight structures for the AI lifecycle	Legal / Compliance
Incident Handling & Change Notification	Outlines how the vendor manages failures and updates to the model	Security / Clinical Engineering

How Censinet Helps Teams Collect and Track Vendor Evidence

Censinet RiskOps™ puts vendor responses, supporting documents, and review notes into one record through a shared assessment workflow. Censinet AI™ speeds up vendor questionnaire completion and summarizes evidence automatically. Human review stays in control, especially for high- and critical-tier tools. Those records then feed into the risk-tiering step that comes next.

How to Evaluate AI Vendor Risk Using HSCC's Approach

HSCC AI Vendor Transparency: 4-Step Due Diligence Framework for Healthcare

Once you have the disclosure package, the next job is simple to describe and harder to do: decide how much review the tool needs. HSCC gives you a clear way to move from vendor evidence to a risk decision without giving every AI tool the same level of scrutiny. The idea is straightforward: use the disclosures to place the tool in a risk tier, then match your due diligence to that tier.

Step 1: Inventory, Use-Case Classification, and Risk Tiering

Before any review starts, you need to know exactly what you're reviewing. HSCC calls this the pre-procurement classification step. It happens before a tool even moves into the procurement pipeline.

Start with the vendor evidence you already collected. Inventory all AI assets - clinical, operational, and infrastructure-level. Then map each tool's data flows, regulated data exposure, and effect on clinical decisions. HSCC's AI Cyber Glossary helps you standardize labels before you assign tiers. That matters more than it may seem. If teams label tools differently, risk review gets messy fast.

Once the inventory is set, assign a risk tier based on the tool's possible effect on patient safety, regulated data, and clinical decision-making.

Risk Tier	Impact Level	What It Requires
Low	Minimal impact on patient safety or operations	Baseline requirements and minimum question sets
Medium	Moderate operational or data impact	Enhanced controls and comprehensive assessments
High	Significant impact on clinical decisions or regulated data	Advanced risk stratification and extensive validation
Critical	Direct impact on life safety or core infrastructure	Maximum due diligence, sophisticated governance, and ongoing monitoring

One more thing: don't stop at the main vendor. Your inventory should also surface third- and fourth-party dependencies. That includes subcontractors, offshore development contributors, and open-source AI components inside the vendor's stack. If those pieces stay hidden, your risk tier may look lower on paper than it is in practice. That tier then sets the review depth for Step 2.

Step 2: Apply Tiered Due Diligence and Ongoing Risk Review

Once a tool has a tier, the review depth should match its risk level. A low-tier scheduling assistant and a high-tier clinical decision tool should not go through the same process. That's the whole point.

For high- and critical-tier tools, the review should stretch past procurement and into implementation, monitoring, incident response, and decommissioning. Each phase needs clear accountability. Vendors should provide a RACI matrix that shows who is responsible for model monitoring, who handles incident response, and who manages end-of-life planning.

Post-deployment monitoring is where many organizations stumble. HSCC treats ongoing review - not just first approval - as a core part of AI governance. That review helps determine whether a vendor stays approved, moves to conditional approval, or needs remediation.

So don't bury reassessment in a procurement folder and call it done. Put periodic review on the governance calendar. Then use those review points to shape contract terms and approval gates.

How to Turn Vendor Transparency Into Contracts, Governance, and Procurement Decisions

Build Enforceable Contract and Governance Requirements

After risk tiering, the next move is simple: put those same evidence needs into the contract and your governance process.

Disclosures on their own don't do much. They need clear terms, named owners, and clear consequences if a vendor falls short. HSCC's seven-phase lifecycle places contract negotiation in Phase 2 and includes sample contract language and vendor questionnaires.

Focus on a small set of contract controls first:

Advance notice of model or training-data changes, especially if updates could change clinical performance.
Audit rights and evidence-refresh expectations so you can check whether vendor claims still hold up over time, not just during the sales process.
Incident notification timelines for AI-specific events - such as adversarial inference attacks or training data leakage - written plainly instead of buried inside broad breach language.

Here’s how each disclosure area connects to a contract control and the team that should own it:

Disclosure Category	Contractual Control	Governance Owner
Model Training Data	Limits on data use; prohibition on training on PHI without explicit consent; notice of training data updates	Data Privacy / Legal
Supply Chain / Subcontractors	Disclosure of all third-party and open-source assets; approval rights for material offshore subcontractors	Procurement / Risk Managers
Model Performance / Drift	Requirements for joint validation; periodic performance reporting; audit rights for model accuracy	Clinical Engineering / Clinical Teams
AI Security Incidents	Specific notification timelines for adversarial attacks or data leakage; incident response coordination	IT / Cybersecurity Teams
Decommissioning	Requirements for secure data deletion and model removal at end-of-life	Compliance / IT

A RACI matrix can keep clinical, operational, compliance, and technical teams on the same page about who owns each control. It also helps avoid the all-too-common problem where everyone is involved, but no one is clearly accountable.

Use the HSCC AI Cyber Glossary to define terms like "training data" and "adversarial inference" right in the contract. That removes room for confusion later.

Censinet RiskOps™ supports this process by routing contract findings to the right governance owners.

Using Disclosures to Approve, Conditionally Approve, Remediate, or Reject a Vendor

Once the review is done, every AI vendor needs a documented outcome. The disclosure package should support one of four decisions:

Decision Outcome	Criteria / Trigger	Required Documentation
Approval	Low or medium risk; evidence meets all HSCC baseline requirements	Risk tiering justification; standard contract terms
Conditional Approval	High risk but manageable; non-critical evidence gaps exist	List of compensating controls; specific review cadence
Remediation Plan	Critical gaps in security or transparency; high safety impact	Detailed remediation roadmap; escalation triggers; vendor milestones
Rejection	Unacceptable safety risk; refusal to disclose training data or supply chain	Rationale for rejection based on HSCC risk framework

The decision should match two things: the quality of the evidence and the tool's risk tier.

Document the rationale for every decision. That means noting which compensating controls are in place, when the next review will happen, and what would trigger escalation. That paper trail matters during audits, and it also makes later reassessments much easier.

Once contracts and decisions are documented, the final step is ongoing monitoring and periodic review.

Conclusion: The New Baseline for AI Due Diligence in Healthcare

HSCC turns AI transparency into enforceable procurement, governance, and monitoring requirements. The standard is specific, risk-tiered disclosure across model governance, data provenance, supply chain dependencies, and security controls - linked straight to the disclosure checklist and risk tiers this guide has covered.

The organizations most likely to handle this well are the ones that make the process repeatable: a structured intake flow, enforceable contracts, a documented decision for every vendor, and a monitoring cadence that doesn't stop after the first approval.

"Cyber safety is patient safety." ^[3]

HSCC's message is direct: AI transparency is patient safety. AI vendor transparency is not just a compliance checkbox - it's a patient safety discipline, and HSCC is giving healthcare teams the tools to handle it that way.

FAQs

What is an AI-BOM?

An AI Bill of Materials (AIBOM) is a transparency tool that documents the parts and supply chain dependencies inside an AI product.

For healthcare organizations, it sheds light on AI components, training data sources, model lineage, APIs, data flows, use cases, and third- and fourth-party subcontractors. That makes it easier to spot hidden risks, surface shadow AI, and map the AI supply chain.

How should we tier AI vendor risk?

Use a structured, risk-based approach early in procurement so the level of oversight fits the tool’s likely effect on patient safety and data privacy.

A simple tiering model works well:

Tier 1: Direct PHI use and clinical decision support; full review
Tier 2: Indirect PHI exposure; moderate review
Tier 3: No PHI access; lighter review

A cross-functional governance committee should register each tool and assign its tier. That gives teams a clear starting point and helps avoid treating every purchase the same way. A tool that touches PHI or shapes care decisions needs much closer scrutiny than one with no PHI access.

What should be in an AI vendor contract?

AI vendor contracts need more than standard software terms. If the tool will touch patient data or support care decisions, the contract should spell out clear guardrails for data use, PHI limits, breach notice, audits, model updates, and post-deployment monitoring.

That means getting specific about questions like these: What data can the vendor use? Where does PHI go? How fast must they report a breach? Can you audit their controls? What happens when the model changes after launch? And who is watching performance once the system is live?

The contract should also deal head-on with liability for AI mistakes, data ownership, and a clear ban on training on patient data without consent. On top of that, you’ll want rollback and suspension rights, plus SLAs that cover uptime, incident response, and performance reporting.

In plain English: if the AI tool fails, drifts, or starts acting in ways you didn’t sign up for, the contract should give you a way to respond fast - not after the damage is done.